It has been shown that RA inhibits EGFR expression at the transcriptional level by targeting the EGFR promoter leading to inhibition of lung cancer cell growth and arrests EGFR-TKI resistant NSCLC cells in the G0/G1 phase of the cell cycle by altering the expression of GATA-binding factor 6 (GATA6) and inhibits the activation of two important pathways involved in lung cancer progression namely EGFR and Wnt signaling to overcome TKI resistance [46]. Here, GATA6 is linked to non-small cell lung carcinoma.